WEIFANG, China, May 17 /PRNewswire-Asia-FirstCall/ -- Shengtai
Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the
Company"), a manufacturer and distributor in China of glucose and starch as pharmaceutical
raw materials and other starch and glucose products, today
announced that it issued financial results for the third quarter of
fiscal year 2010 (nine months ended March
31, 2010) before the opening of the stock market in USA on
Monday, May 17, 2010. Management will
conduct a conference call on Tuesday, May
18, 2010 at 8:00 A.M. Eastern
Daylight Time to discuss these results. A question and
answer session will follow management's presentation.
Mr. Hu Ye (CFO), and Ms.
Shenglian Iris Wang (Investor Relations Manager) will be the
primary speakers on the call.
To participate, please call the following numbers ten minutes
before the call start time:
Phone Number + 1 (877) 407-8035 (North America)
Phone Number + 1 (201) 689-8035 (International)
A replay of the call will be available through May 25, 2010, at 11:59
P.M. Eastern Daylight Time. For the replay, please call:
Phone Number +1 (877) 660-6853 (North America)
Phone Number +1 (201) 612-7415 (International)
Account Number: 286
Conference ID Number: 350980
About Shengtai Pharmaceutical, Inc.
Shengtai Pharmaceutical, Inc. through its wholly owned
subsidiary, Shengtai Holding, Inc. (SHI), and the Chinese operating
company of Weifang Shengtai Pharmaceutical Co., Ltd., is a
manufacturer and distributor in china of glucose and starch
products as pharmaceutical raw materials, other starch products and
other glucose products such as corn meals, food and beverage
glucose and dextrin. For more information about Shengtai
Pharmaceutical, Inc., please visit
http://www.shengtaipharmaceutical.com .
Forward Looking Statements
Certain statements in this press release and oral statements
made by the Company constitute forward-looking statements
concerning the Company's business and products. These statements
include, without limitation, statements regarding our ability to
prepare the Company for growth, the Company's planned capacity
expansion and predictions and guidance relating to the Company's
future financial performance. We have based these forward- looking
statements largely on our current expectations and projections
about future events and financial trends that we believe may affect
our financial condition, results of operations, business strategy
and financial needs, but they involve risks and uncertainties that
could cause actual results to differ materially from those in the
forward-looking statements, which may include, but are not limited
to, such factors as unanticipated changes in product demand
especially in the pharmaceutical industry, pricing and demand
trends for the Company's products, changes to government
regulations, risk associated with operation of the Company's new
facilities, risk associated with large- scale implementation of the
Company's business plan, the ability to attract new customers,
ability to increase its product's applications, cost of raw
materials, downturns in the Chinese economy, and other information
detailed from time to time in the Company's filings and future
filings with the United States Securities and Exchange Commission.
Investors are urged to consider these factors carefully in
evaluating the forward-looking statements herein and are cautioned
not to place undue reliance on such forward-looking statements,
which are qualified in their entirety by this cautionary statement.
The forward-looking statements made herein speak only as of the
date of this press release and the Company undertakes no duty to
update any forward-looking statement to conform the statement to
actual results or changes in the Company's expectations.
For more information, please contact:
Shengtai Pharmaceutical, Inc.
Mr. Hu Ye
Chief Financial Officer
Tel: +86-139-1157-3505
Email: shengtaicfo@hotmail.com
Shengtai Pharmaceutical, Inc.
Ms. Shenglian Iris Wang
Investor Relations Manager
Tel: +86-536-6295802
Email: shengtaiadm@hotmail.com
SOURCE Shengtai Pharmaceutical, Inc.